Inventiva announced the completion of the last patient's final 72-week visit in its NATiV3 Phase 3 clinical trial for lanifibranor, a treatment for metabolic dysfunction-associated steatohepatitis (MASH). The trial enrolled 1,009 patients in the main cohort and 410 in an exploratory cohort. Topline results are expected in Q4 2026, with potential regulatory submission in H1 2027 and a U.S. launch in 2028 if approved. The company also updated its H1 2026 financial results date to September 28, 2026. Inventiva is a clinical-stage biopharmaceutical company focused on developing therapies for MASH.
